n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Thursday's Health Winners & Losers

AstraZeneca is rising.

Tuesday's Health Winners & Losers

Cephalon shares decline in value.

Eye on Genentech's Lucentis

The eye drug's sales will be key in today's postclose earnings.

Find the Biotech Stars at JPMorgan Confab

Investors will get a key sector overview next week.

Rituxan Worries Hit Biogen, Genentech

Shares of both are lower after two patients die while taking the drug.

Elan Crowns King in Aribtration

King will pay out $49 million in a development dispute.

Thursday's Health Winners & Losers

Forest Labs falls on a big buyout.

Cramer's 'Mad Money Lightning Round': USG Glee

Cramer likes the maker of gypsum wallboard.

Abbott Makes Deal for Kos

The acquisition is valued at $3.7 billion.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Sirna almost doubles after Merck's buyout offer.

Sales Jump at Biogen Idec

Quarterly earnings rise sharply.

Wednesday's Health Winners & Losers

Forest Labs is falling.

Revenue Slips at Elan

The company says it will take 'several quarters' before it can assess the prospects for Tysabri.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Elan is higher.

Tysabri Effective in Crohn's Trial

The drug helps maintain remission in patients who were treated for longer than two years.

Tuesday's Health Winners & Losers

Shares of Neurochem drop.

Wednesday's Health Winners & Losers

Biogen and Elan are higher.

Tysabri Cleared in Canada

Tysabri Cleared in Canada

The drug can be used for treating relapsing-remitting forms of MS.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Cytokinetics is lower.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Labopharm plunges.

Tysabri Delays MS Relapse: Data

Tysabri Delays MS Relapse: Data

The drug also improves the cognitive function of multiple sclerosis patients.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Biocryst is higher.

Elan Inks Alzheimer's Deal

Elan Inks Alzheimer's Deal

The company and Transition Therapeutics are collaborating to develop a new treatment.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

AnorMed jumps.

Analyst Worries About Tysabri

Deborah Knobelman says the drug's U.S. sales this year will likely be much lower than she expected.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Genzyme is dropping.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Genentech is falling.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Boston Scientific is falling, but Zoll rises.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Mylan falls, but Novogen is higher.

Thursday's Health Stock Winners & Losers

Thursday's Health Stock Winners & Losers

Dendreon rises, while Genzyme declines.